OncoMed to Present at the Cantor Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will present a corporate update at the 2018 Cantor Global Healthcare Conference in New York, NY on Monday, October 1, 2018 at 5:15 pm Eastern Time.
To access the live webcast and subsequent archived recording of this presentation, or other company presentations, please visit OncoMed's website at www.oncomed.com/invest/events.cfm. A replay will be available for 30 days following the date of the event.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Product candidates in OncoMed’s portfolio include navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), etigilimab (anti-TIGIT, OMP-313M32), GITRL-Fc (OMP-336B11) and rosmantuzumab (anti-RSPO3, OMP-131R10). OncoMed also continues to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Contacts Sylvia Wheeler sylvia.wheeler@oncomed.com |
Alexandra Santos asantos@wheelhouselsa.com |
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
![](https://www.einpresswire.com/tracking/article.gif?t=2&a=LBDjuGYLDnVxmibm&i=D_vZY0CrZgEd8o2j)